DDH‑LSD versus LSD: comparing duration, effects, and pharmacokinetics
Official title: Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD
Run by University Hospital, Basel, Switzerland · NCT07309471 · Data updated 2026-11-12
This study will test whether DDH‑LSD produces LSD‑like psychedelic effects but for a shorter time in healthy adult volunteers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | March 6, 2026 |
| Main results expected | July 2028 |
| Study ends | July 2028 |
| Registry record updated | March 10, 2026 |
| Trial ID | NCT07309471 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 25–65 who speak German, have BMI 18–32 kg/m2, no major medical or psychiatric history, and who agree to study rules and abstain from disallowed substances are ideal candidates.
✕Probably not a fit
People with significant medical or psychiatric conditions, a history of psychosis or bipolar disorder, uncontrolled blood pressure, pregnant people, or those seeking treatment for psychiatric illness are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study has two parts: an open‑label dose‑escalation in healthy volunteers to find a DDH‑LSD dose that produces clear but tolerable psychoactive effects, followed by a randomized, double‑blind, placebo‑controlled cross‑over comparing that DDH‑LSD dose with LSD and placebo. Each participant attends multiple supervised study days with comprehensive measurement of subjective effects, vital signs, and blood sampling for pharmacokinetics. The design allows within‑subject comparison of effect magnitude and time course between DDH‑LSD and LSD. The goal is to generate first‑in‑human data on safety, subjective profile, and duration of DDH‑LSD relative to LSD.
Why it matters
Potential benefit: If successful, DDH‑LSD could offer a shorter‑acting psychedelic option that is easier to schedule and monitor in research or therapeutic settings.
How similar studies have gone: LSD and several analogs have been studied before and their pharmacology is well characterized, but DDH‑LSD is a novel compound and this is a first‑in‑human comparison.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age between 25 and 65 years old 2. Sufficient understanding of the German language 3. Understanding of procedures and risks associated with the study 4. Willing to adhere to the protocol and signing of the consent form 5. Willing to refrain from the consumption of illicit psychoactive substances during the study 6. Abstaining from xanthine-based liquids from the evenings prior to the study sessions and during the sessions 7. Willing not to operate heavy machinery within 48 h of substance administration 8. Willing to use effective contraceptive measures throughout study participation 9. Body mass index between 18-32 kg/m2 Exclusion Criteria: 1. Chronic or acute medical condition 2. Current or previous major psychiatric disorder 3. Psychotic disorder or bipolar disorder in first-degree relatives 4. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg) 5. Use of hallucinogenic substances (not including cannabis) more than 20 times or any time within the previous two months 6. Pregnancy or currently breastfeeding 7. Participation in another clinical trial (currently or within the last 30 days) 8. Use of medication that may interfere with the effects of the study medication 9. Tobacco smoking (\>10 cigarettes/day) 10. Consumption of alcoholic beverages (\>20 drinks/week)
Where it's running
-
University Hospital Basel
Basel, Switzerland Recruiting
Study contacts
- Study coordinator: Matthias Liechti, Prof. MD
- Email: matthias.liechti@usb.ch
- Phone: +41 61 328 68 68
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting bowel leaks after colorectal surgery with a computer model and surgeon input
This study tests a computer model that predicts anastomotic leaks after colorectal surgery, and sees if adding surgeons’ intuition improves the predictions.
-
Active surveillance after immunotherapy for MMR-deficient colorectal and GI cancers
This study looks at whether some patients with non-metastatic, MMR-deficient or MSI-H colorectal cancers can skip surgery after a strong response to immunotherapy.
-
PCI Registry at University Hospital Basel for Complex Coronary Procedures
This registry collects real-world data from adults undergoing percutaneous coronary interventions at University Hospital Basel to see how different treatments like drug-eluting stents, drug-coated balloons, and bioresorbable scaffolds perform in diverse patients.
-
Severe Complications During VT/PVC Ablation
This study looks at real-world cases to see what severe complications occur during VT or PVC ablations and how patients are managed afterward.
-
Visioning III: Five-year follow-up for MRI-based prostate cancer screening
This study tests a repeat MRI-based screening approach for men who previously had no cancer signs, to see if a negative bpMRI reliably predicts no significant cancer for at least five years.
-
Oxytocin in postmenopausal and premenopausal women
Researchers will test whether cumulative endogenous neurophysin I, a surrogate for oxytocin, differs over a month between premenopausal and postmenopausal women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.